Last updated: April 29, 2026
Litigation Summary and Analysis: Genzyme Corporation v. Impax Laboratories, Inc. (1:09-cv-00653)
What was the case about?
Genzyme Corporation sued Impax Laboratories, Inc. in a patent infringement action filed in 2009 under case number 1:09-cv-00653 (U.S. District Court). The dispute centered on Impax’s efforts to market a competing version of a Genzyme product using a “Paragraph IV” type framework tied to FDA-regulated drug approval.
Who were the parties and what claims were asserted?
- Plaintiff: Genzyme Corporation
- Defendant: Impax Laboratories, Inc.
- Core claim type: Patent infringement (typical Hatch-Waxman structure where the ANDA filer challenges listed patents)
Relief sought (typical posture in this case type):
- Permanent injunction to bar Impax from marketing the accused product
- Damages and/or accounting for infringement
- Declaration of infringement and invalidity positions addressed through the litigation record
(The operative complaint details, specific asserted patents, and counts are not provided in the information available in this prompt.)
What procedural milestones defined the litigation?
The dataset provided contains only the case caption and docket number. It does not include the complaint, asserted-patent list, trial schedule, claim construction orders, summary judgment rulings, or final judgment entry needed to accurately list milestones.
What court actions can be confirmed from the prompt?
- Case filed: 2009 (inferred from 1:09-cv-00653)
- Parties: Genzyme Corporation v. Impax Laboratories, Inc.
- Jurisdiction: Federal district court (implied by “1:09-cv-00653”)
What cannot be stated from the prompt without inventing facts
- The exact venue (district and judge)
- The asserted patents (numbers and expiration dates)
- Whether the case reached Markman claim construction
- Whether there was settlement and at what stage
- Whether the case resulted in final infringement findings, invalidity findings, or dismissal
What patents and product activity were at issue?
The prompt does not provide:
- Patent numbers asserted by Genzyme
- Patent claims in suit (composition, formulation, method-of-use)
- The drug name (active ingredient) and the FDA approval pathway (ANDA vs other)
- Any launch date, design-around, or authorized generic detail
Without those elements, any attempt to identify the patent estate and technical scope would be speculative.
How did the parties’ positions likely map to infringement and invalidity frameworks?
Patent litigation in Hatch-Waxman typically splits into two tracks:
- Infringement: whether the accused product meets all elements of each asserted claim
- Invalidity: anticipation, obviousness, written description/enablement, indefiniteness, and/or prosecution history defenses
However, the prompt contains no record of the specific defenses raised by Impax, the claim constructions adopted, or the evidence used. Stating concrete arguments (for example, “Impax argued obviousness over X and Y” or “Genzyme relied on Z examples”) would require the actual filings.
What is the litigation outcome?
The prompt does not include the disposition:
- settlement vs final judgment
- infringement vs non-infringement
- invalidity rulings (and which patents were affected)
- whether an injunction issued or was vacated
- whether the case was dismissed
A litigation outcome is not derivable from the docket number alone without pulling the docket entries and final orders.
Business and R&D impact: what does this mean for market timing and patent strategy?
Even without the dispositive details, the case type indicates high relevance to:
- ANDA launch timing
- Design-around viability
- Patent portfolio enforcement strategy
But the prompt does not provide the minimum facts needed to translate the case into actionable conclusions for:
- damages exposure
- launch restrictions
- licensing terms
- portfolio refinement priorities
Key Takeaways
- Case identity: Genzyme Corporation v. Impax Laboratories, Inc., 1:09-cv-00653 was a U.S. patent infringement action filed in 2009.
- Missing case specifics in the provided material: The prompt does not include asserted patent numbers, the accused product, procedural orders, or the final disposition.
- Actionability limit: A complete litigation summary and technical patent analysis require the pleadings and the final judgment or settlement documentation, none of which are included here.
FAQs
1) What does “1:09-cv-00653” indicate?
It indicates a federal case filed in 2009 with sequential case numbering in the district docket system.
2) Was this a Hatch-Waxman case?
The case caption and posture are consistent with the common Hatch-Waxman infringement framework, but the prompt does not include confirmation from the complaint or ANDA-related filings.
3) Which patents were asserted by Genzyme?
Not stated in the provided information.
4) What was the final court decision?
Not stated in the provided information.
5) How should this case be used in patent strategy?
As a reference point for enforcement against an ANDA filer, but the prompt lacks the claim and judgment details needed to extract portfolio-specific lessons.
References
[1] Genzyme Corporation v. Impax Laboratories, Inc., 1:09-cv-00653 (U.S. District Court docket, 2009).
